<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Int AIDS Soc</journal-id><journal-id journal-id-type="iso-abbrev">J Int AIDS Soc</journal-id><journal-id journal-id-type="publisher-id">JIAS</journal-id><journal-title-group><journal-title>Journal of the International AIDS Society</journal-title></journal-title-group><issn pub-type="epub">1758-2652</issn><publisher><publisher-name>International AIDS Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25394061</article-id><article-id pub-id-type="pmc">4224811</article-id><article-id pub-id-type="publisher-id">19554</article-id><article-id pub-id-type="doi">10.7448/IAS.17.4.19554</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Sessions &#x02013; Abstract P022</subject></subj-group></article-categories><title-group><article-title>Changes in lipid levels after 48 weeks of dual versus triple therapy observed in the GARDEL study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cahn</surname><given-names>Pedro</given-names></name><xref ref-type="aff" rid="AF0001_19554">1</xref></contrib><contrib contrib-type="author"><name><surname>Andrade Villanueva</surname><given-names>Jaime</given-names></name><xref ref-type="aff" rid="AF0002_19554">2</xref></contrib><contrib contrib-type="author"><name><surname>Arribas</surname><given-names>Jose</given-names></name><xref ref-type="aff" rid="AF0003_19554">3</xref></contrib><contrib contrib-type="author"><name><surname>Gatell</surname><given-names>Jose</given-names></name><xref ref-type="aff" rid="AF0004_19554">4</xref></contrib><contrib contrib-type="author"><name><surname>Lama</surname><given-names>Javier</given-names></name><xref ref-type="aff" rid="AF0005_19554">5</xref></contrib><contrib contrib-type="author"><name><surname>Norton</surname><given-names>Michel</given-names></name><xref ref-type="aff" rid="AF0006_19554">6</xref></contrib><contrib contrib-type="author"><name><surname>Patterson</surname><given-names>Patricia</given-names></name><xref ref-type="aff" rid="AF0001_19554">1</xref></contrib><contrib contrib-type="author"><name><surname>Sierra Madero</surname><given-names>Juan</given-names></name><xref ref-type="aff" rid="AF0007_19554">7</xref></contrib><contrib contrib-type="author"><name><surname>Sued</surname><given-names>Omar</given-names></name><xref ref-type="aff" rid="AF0001_19554">1</xref></contrib><contrib contrib-type="author"><name><surname>Ines Figueroa</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="AF0001_19554">1</xref></contrib><contrib contrib-type="author"><name><surname>Jose Rol&#x000f3;n</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="AF0001_19554">1</xref></contrib></contrib-group><aff id="AF0001_19554"><label>1</label>Clinical Research, Fundacion Huesped, Ciudad Aut&#x000f3;noma de Buenos Aires, Argentina</aff><aff id="AF0002_19554"><label>2</label>Unidad de HIV, Hospital Civil de Guadalajara &#x0201c;Fray Antonio Alcalde&#x0201d;, Guadalajara, Mexico</aff><aff id="AF0003_19554"><label>3</label>Hospital Universitario La Paz, IdiPAZ, Madrid, Spain</aff><aff id="AF0004_19554"><label>4</label>Infectious Unit, Hospital Cl&#x000ed;nic/IDIBAPS, University of Barcelona, Barcelona, Spain</aff><aff id="AF0005_19554"><label>5</label>Clinical Research, Asociaci&#x000f3;n Civil Impacta Salud y Educaci&#x000f3;n (IMPACTA), Lima, Peru</aff><aff id="AF0006_19554"><label>6</label>Virology, Global Pharmaceutical Research and Development, AbbVie, Medical Affairs Therapeutic Area, Chicago, IL, USA</aff><aff id="AF0007_19554"><label>7</label>Department of Infectious Diseases, Instituto Nacional de Ciencias M&#x000e9;dicas y Nutrici&#x000f3;n Salvador Zubir&#x000e1;n, Mexico City, Mexico</aff><pub-date pub-type="epub"><day>02</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>17</volume><issue>4Suppl 3</issue><elocation-id content-type="doi">19554</elocation-id><permissions><copyright-statement>&#x000a9; 2014 Cahn P et al; licensee International AIDS Society</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1_19554"><title>Introduction</title><p>Treatment with ritonavir-boosted protease inhibitors and nucleoside analogues frequently leads to rises in lipids, which might increase the cardiovascular risk. The aim of this study was to describe changes in lipid levels among HIV positive patients participating in the GARDEL study.</p></sec><sec id="st2_19554"><title>Materials and Methods</title><p>The GARDEL study compared the efficacy and safety of a dual therapy (DT) combination of LPV/r 400/100 mg BID+3TC 150 mg BID to a triple therapy (TT) with LPV/r 400/100 mg BID+3TC or FTC and a third investigator-selected NRTI in fixed-dose combination among HIV+ treatment na&#x000ef;ve patients. We compared changes in lipid levels from baseline to week 48 in both arms.</p></sec><sec id="st3_19554"><title>Results</title><p>Patient's characteristics were well balanced regarding mean baseline total cholesterol (157 mg/dL DT, 154 mg/dL TT), triglycerides (142 mg/dL DT, 139 mg/Dl TT), LDL-C (94 mg/dL DT, 91 mg/dL TT) and HDL-C (36 mg/dL DT, 35 mg/dL TT). Changes in total cholesterol, LDL-C and HDL-C were higher in DT arm, compared to TT (32% DT vs 26% TT for cholesterol; 25% DT vs 16% TT for LDL and 33% DT vs 28% TT for HDL). Increase in triglycerides was higher in TT compared to DT (55% DT vs 92% TT) (<xref ref-type="table" rid="T0001_19554">Table 1</xref>). In TT arm LDL-C and total cholesterol elevations were lower among patients receiving TDF compared to those treated with ZDV or ABC.
</p></sec><sec id="st4_19554"><title>Conclusion</title><p>Changes in lipid parameters were observed in both arms. Albeit the increase was numerically higher for cholesterol (total and LDL-C) in DT arm while TT arm had higher increases in TG; no difference was observed when week 48 values were compared with the NCEP ATP III goals for cardiovascular risk reduction [<xref rid="CIT0001_19554" ref-type="bibr">1</xref>]. So, the DT strategy, even missing the lipid-lowering effect observed with tenofovir, does not seem to add significant risk to patients treated with this novel strategy.</p></sec></abstract></article-meta></front><body><table-wrap id="T0001_19554" position="float"><label>Table 1</label><caption><p>Lipid Concentrations at Baseline and Week 48 and Mean Percentual Change</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">&#x02002;DT (n=214)</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1"/><th colspan="1" align="left" rowspan="1"><hr/></th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">BSL<xref ref-type="table-fn" rid="TF0001_19554">*</xref></th><th align="center" rowspan="1" colspan="1">W48<xref ref-type="table-fn" rid="TF0001_19554">*</xref></th><th align="center" rowspan="1" colspan="1">Mean percentage change (%)<xref ref-type="table-fn" rid="TF0002_19554">a</xref>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total Cholesterol</td><td align="center" rowspan="1" colspan="1">157</td><td align="center" rowspan="1" colspan="1">206</td><td align="center" rowspan="1" colspan="1">+32</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL-C</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">+33</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL-C</td><td align="center" rowspan="1" colspan="1">94</td><td align="center" rowspan="1" colspan="1">117</td><td align="center" rowspan="1" colspan="1">+25</td></tr><tr><td align="left" rowspan="1" colspan="1">Non-LDL-C</td><td align="center" rowspan="1" colspan="1">120</td><td align="center" rowspan="1" colspan="1">157</td><td align="center" rowspan="1" colspan="1">+30</td></tr><tr><td align="left" rowspan="1" colspan="1">TGs</td><td align="center" rowspan="1" colspan="1">142</td><td align="center" rowspan="1" colspan="1">222</td><td align="center" rowspan="1" colspan="1">+55</td></tr></tbody></table><table-wrap-foot><fn id="TF0001_19554"><label>*</label><p>Units:m g/dl, mean</p></fn><fn id="TF0002_19554"><label>a</label><p>Percentage increase between baseline and week 48. Mean percentage change was calculated at each specific time point for each individual patient as (concentration [week X] - concentration [baseline]) / (concentration [baseline])&#x000d7;100.</p></fn></table-wrap-foot></table-wrap></body><back><ref-list><title>Reference</title><ref id="CIT0001_19554"><label>1</label><element-citation publication-type="journal"><article-title>Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)</article-title><source>JAMA</source><year>2001</year><volume>285</volume><fpage>2486</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">11368702</pub-id></element-citation></ref></ref-list></back></article>